- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | SenzaGen AB: Report from AGM of SenzaGen AB on 14 May 2025 | 56 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 14 May 2025 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 14.05. | SenzaGen AB: SenzaGen's interim report January-March 2025: High activity amid global turbulence - building for growth | 54 | GlobeNewswire (Europe) | Message from the CEO"The quarter was shaped by a volatile global environment, adverse foreign exchange effects, and longer customer decision cycles, which have together impacted sales growth and consequently... ► Artikel lesen | |
| 22.04. | SenzaGen AB: FDA signals shift towards non-animal testing in the pharmaceutical industry - strengthens SenzaGen's commercial potential | 79 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has announced the initiation of its planned phase-out of animal testing in the pharmaceutical industry - a decisive step towards non-animal testing methods.... ► Artikel lesen | |
| 13.02. | SenzaGen AB: GARD going stronger and subsidiary enters new phase | 229 | GlobeNewswire (Europe) | Message from the CEO"2024 was yet another strong year for SenzaGen with record growth for our core business GARD®, with sales increasing by 53% to nearly SEK 40 million. The Group's total revenue increased... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 08.11.24 | SenzaGen AB: SenzaGen's interim report January-September 2024: Strong quarter with over 30% growth | 126 | GlobeNewswire (Europe) | Message from the CEO"We are coming out of yet another successful quarter with strong results and positive growth signals for the future. In the third quarter of the year, our year-on-year sales grew... ► Artikel lesen | |
| 22.08.24 | SenzaGen AB: SenzaGen's interim report January-June 2024: 30% growth in Q2, and funding secured for new commercial growth projects | 104 | GlobeNewswire (Europe) | Message from the CEO
"We have continued to deliver very strong sales growth with cost controls in the second quarter of the year. Sales increased to SEK 14.7 million in the quarter, representing 30%... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,535 | -0,81 % | Qiagen NV-Aktie läuft heute schlechter (37,92 €) | An der Börse notiert die Aktie von Qiagen NV gegenwärtig leichter. Zuletzt zahlten Investoren für die Aktie 37,92 Euro. Der Anteilsschein von Qiagen NV verzeichnet derzeit einen Abschlag von 0,56 Prozent.... ► Artikel lesen | |
| TEMPUS AI | 59,32 | +2,05 % | Tempus AI: Wieder auf dem Weg zum Allzeithoch? | Die Tempus AI-Aktie ist erst seit Mai 2024 an der Nasdaq gelistet und zeigte seither mehrfach beeindruckende Momentum-Anstiege Den vollständigen Artikel lesen ... ► Artikel lesen | |
| EVOTEC | 7,038 | 0,00 % | Evotec-Aktie: Kurs legt zu (7,174 €) | Im deutschen Wertpapierhandel liegt die Evotec-Aktie aktuell im Plus. Das Wertpapier kostete zuletzt 7,17 Euro. Ein Wertanstieg von 2,84 Prozent steht gegenwärtig für der Anteilsschein von Evotec zu... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 42,970 | -0,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,280 | +0,15 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| IMMUNOVANT | 14,560 | +1,11 % | Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 | Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO... ► Artikel lesen | |
| VIGIL NEUROSCIENCE | 7,885 | +241,34 % | Vigil Neuroscience-Aktie +246%: Sanofi schnappt zu | Anleger, die in die Vigil Neuroscience-Aktie investiert haben, dürfte sich freuen. Der französische Pharmariese Sanofi will sich das US-amerikanische Biotech-Unternehmen, das auf degenerative neurologische... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 30,170 | +0,13 % | Envirotech Vehicles, Inc. Signs Letter of Intent to Acquire Kymera - A Company Twice Featured On ABC's Shark Tank | HOUSTON, TX / ACCESS Newswire / May 15, 2025 / Envirotech Vehicles, Inc. (NASDAQ:EVTV) ("Envirotech" or the "Company") today announced the signing of a non-binding Letter of Intent ("LOI") to acquire... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,900 | +1,19 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
| INOZYME PHARMA | 3,960 | +0,13 % | BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,750 | +1,42 % | Summit Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ARCELLX | 65,34 | -0,34 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| BIONTECH | 87,60 | -0,06 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,180 | +0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 6,270 | -0,63 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen |
SENZAGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,41 % bei einem Aktienkurs von 0,455 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.